Multicenter Clinical Comparison Between Anti‐ NXP2 and Anti‐ TIF1 ‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐ NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies
The Journal of Dermatology · 2026-11 · 53 (11) · 1626-1637
DOI: 10.1111/1346-8138.70490 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Dermatology, online erschienen am 16.09.2026. Verfasst von Satoshi Kamiya und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Autoantibodies, Dermatomyositis, Transcription Factors, RNA-Binding Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency.
Abstract (Originalsprache)
We aimed to measure anti‐nuclear matrix protein 2 antibody (anti‐NXP2) titers in patients with anti‐NXP2‐positive idiopathic inflammatory myopathies, investigate whether these titers are associated with clinical manifestations, malignancy risk, and treatment response, and compare the clinical and serological features between anti‐NXP2‐positive and anti‐transcriptional intermediary factor 1‐γ antibody (anti‐TIF1‐γ)‐positive dermatomyositis in order to identify practical indicators for differentiating the two subsets. We established a newly optimized in‐house enzyme‐linked immunosorbent assay for the quantitative measurement of anti‐NXP2. After excluding two of the 34 initially identified patients with anti‐NXP2 antibody reactivity, we used the assay to analyse sera from 32 patients with anti‐NXP2‐positive idiopathic inflammatory myopathy. Clinical correlations between anti‐NXP2 titers and inflammatory indices, cardiothoracic ratio, malignancy status, and longitudinal changes after immunosuppressive therapy were examined. We developed a novel clinical scoring system to differentiate between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. The anti‐TIF1‐γ‐positive patients showed a higher frequency of classic dermatomyositis skin manifestations, whereas the anti‐NXP2‐positive patients had significantly higher creatine kinase, aldolase, and lactate dehydrogenase levels, indicating more prominent muscle involvement. Anti‐NXP2 titers correlated with erythrocyte sedimentation rate and cardiothoracic ratio and were significantly higher in patients with malignancy in the anti‐NXP2‐positive idiopathic inflammatory myopathy patients. Longitudinal analyses demonstrated declines in antibody titers after immunosuppressive treatment. Our scoring system, incorporating age at onset, Gottron's sign, creatine kinase, lactate dehydrogenase, and malignancy status, highly accurately distinguished between anti‐NXP2‐positive and anti‐TIF1‐γ‐positive myositis. Anti‐NXP2 titers reflect systemic inflammation, cardiac involvement, and malignancy risk in anti‐NXP2‐positive idiopathic inflammatory myopathy. The observed decline in anti‐NXP2 titers after therapy suggests the potential utility of these titers as biomarkers for longitudinal disease assessment and stratifying malignancy risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
- Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Dermatology, Saiseikai Matsusaka General Hospital, Matsusaka, Mie, Japan.
- Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
- Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
- Department of General Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
ORCID-Profile: Satoshi Kamiya, Mariko Ogawa-Momohara, Yoshinao Muro, Satoko Yuasa, Masato Kakeda, Kimiko Nakajima, Mitsuyo Kinjo, Takako Hashimoto, Ken Yoshida, Takuya Takeichi, Haruka Koizumi, Eori Noda, Masashi Akiyama
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Kamiya, S., Ogawa-Momohara, M., Muro, Y., Yamashita, Y., Yuasa, S., Kakeda, M., Nakajima, K., Morita, H., Kinjo, M., Hashimoto, T., Yoshida, K., Takeichi, T., Koizumi, H., Akashi, N., Noda, E., & Akiyama, M. (2026). Multicenter Clinical Comparison Between Anti‐ NXP2 and Anti‐ TIF1 ‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐ NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies. The Journal of Dermatology, 53(11), 1626-1637. https://doi.org/10.1111/1346-8138.70490
Vancouver
Kamiya S, Ogawa-Momohara M, Muro Y, Yamashita Y, Yuasa S, Kakeda M, et al. Multicenter Clinical Comparison Between Anti‐ NXP2 and Anti‐ TIF1 ‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐ NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies. The Journal of Dermatology. 2026;53(11):1626-1637. doi:10.1111/1346-8138.70490
BibTeX
@article{Kamiya2026,
author = {Kamiya, Satoshi and Ogawa-Momohara, Mariko and Muro, Yoshinao and Yamashita, Yuta and Yuasa, Satoko and Kakeda, Masato and Nakajima, Kimiko and Morita, Hiroyuki and Kinjo, Mitsuyo and Hashimoto, Takako and Yoshida, Ken and Takeichi, Takuya and Koizumi, Haruka and Akashi, Norika and Noda, Eori and Akiyama, Masashi},
title = {Multicenter Clinical Comparison Between Anti‐ NXP2 and Anti‐ TIF1 ‐γ Antibody‐Positive Myositis, and Analysis of the Clinical Significance of Anti‐ NXP2 Antibody Titers in Idiopathic Inflammatory Myopathies},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {11},
pages = {1626--1637},
doi = {10.1111/1346-8138.70490}
}
EUVIMED